Equities
  • Price (CHF)101.15
  • Today's Change0.739 / 0.74%
  • Shares traded2.37k
  • 1 Year change+23.96%
  • Beta0.4955
Data delayed at least 20 minutes, as of Feb 13 2026 17:15 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.

  • Revenue in CHF (TTM)4.02bn
  • Net income in CHF192.40m
  • Incorporated2017
  • Employees6.13k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GALE:SWX since
announced
Transaction
value
Puravita AGDeal completed16 Dec 202516 Dec 2025Deal completed7.77%--
Diagnostics Group GmbHDeal completed02 Jul 202502 Jul 2025Deal completed15.26%--
Data delayed at least 15 minutes, as of Feb 13 2026 16:34 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.